4-Sep-2026
Most shorted stocks on Wall Street
Seeking Alpha News (Wed, 2-Sep 10:28 AM ET)
Most and least shorted mid- to mega-cap healthcare stocks at the end of August
Seeking Alpha News (Wed, 2-Sep 10:00 AM ET)
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
Globe Newswire (Tue, 1-Sep 7:00 AM ET)
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
Globe Newswire (Mon, 31-Aug 7:00 AM ET)
Globe Newswire (Tue, 4-Aug 7:00 AM ET)
Globe Newswire (Thu, 23-Jul 7:00 AM ET)
Globe Newswire (Thu, 18-Jun 7:00 AM ET)
Market Chameleon (Tue, 19-May 7:18 AM ET)
Market Chameleon (Tue, 24-Feb 3:43 AM ET)
Market Chameleon (Mon, 12-Jan 6:15 AM ET)
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Beam Therapeutics trades on the NASDAQ stock market under the symbol BEAM.
As of September 4, 2026, BEAM stock price climbed to $29.66 with 1,047,770 million shares trading.
BEAM has a beta of 2.49, meaning it tends to be more sensitive to market movements. BEAM has a correlation of 0.21 to the broad based SPY ETF.
BEAM has a market cap of $3.05 billion. This is considered a Mid Cap stock.
Last quarter Beam Therapeutics reported $490,000 in Revenue and -$1.18 earnings per share. This fell short of revenue expectation by $-18 million and missed earnings estimates by -$.07.
In the last 3 years, BEAM traded as high as $49.50 and as low as $13.53.
The top ETF exchange traded funds that BEAM belongs to (by Net Assets): ARKE, ARKK, XBI, VTI, ARKG.
BEAM has outperformed the market in the last year with a return of +60.0%, while the SPY ETF gained +19.8%. However, in the most recent history, BEAM shares have underperformed the stock market with its stock returning -9.7% in the last 3 month period and -0.3% for the last 2 week period, while SPY has returned +2.0% and +0.6%, respectively.
BEAM support price is $28.35 and resistance is $30.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BEAM shares will trade within this expected range on the day.
